ACTRN12621000228886Completed未知
A randomized placebo-controlled pilot trial on palmitoylethanalomide and curcumin for pain management in patients with chronic pain
Integria Healthcare (Australia) Pty Ltd.0 sites45 target enrollmentStarted: March 4, 2021Last updated:
Conditions
Trial Snapshot
- Phase
- 未知
- Status
- Completed
- Enrollment
- 45
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
- Allocation
- Randomised controlled trial
- Primary Purpose
- Treatment
- Masking
- Blinded (masking used)
Eligibility Criteria
- Ages
- 18 Years to 75 Years (—)
- Sex
- All
Inclusion Criteria
- •Participants meeting the following criteria to be included in the study:
- •- Adults with chronic pain – defined as persistent pain for 12 weeks or more.
- •- Average pain score of 4 or >4 on the visual analogue scale (0-10) for related pain intensity in 3-day diary.
Exclusion Criteria
- •Participants meeting the following criteria to be excluded from the study:
- •- Diagnosed with any of the following medical conditions: neurological disease, gallstones or bile duct obstruction, cancer, currently unwell with acute infection or fever.
- •- Cause of chronic pain is related to a hormonal condition such as menstrual pain or endometriosis, or is autoimmune in nature.
- •- Currently experiencing acute pain unrelated to chronic pain.
- •- In poor general health or baseline blood tests shows abnormal results that require further investigation (as evaluated by PI).
- •- Taking any of the following medications: anti-platelet or anti-coagulant medication, steroids, turmeric or curcumin or PEA supplements, within previous four weeks.
- •- Taking any herbal or nutritional supplements, unless consistently taking for four weeks or more and planning to continue with them throughout the study. Patients with inconsistent use may choose to stop taking the supplements and be re-evaluated for study entry after one week.
- •- Pregnancy, planned pregnancy, or currently breastfeeding.
- •- Planned surgery within two months.
- •- Allergy/sensitivity to study drugs or their formulations.
- •- Individuals that have participated in another clinical trial in the last 30 days.
- •- Inability or unwillingness of subject or legally acceptable representative to give written informed consent.
Investigators
Similar Trials
Completed
Phase 2
The safety and efficacy of a locally available probiotic in premature infants.ACTRN12609000374268Womens and Childrens Health Service120
Completed
Not Applicable
A pilot randomized placebo controlled study of the Neutrophil Elastase Inhibitor, Sivelestat, in Patients Undergoing Cardiac Surgerycoronary artery bypass patientsJPRN-UMIN000001687agoya University Hospital Department of Cardiac Surgery20
Active, not recruiting
Phase 1
The influence of the medication Willfact on the blood loss of patient during the use of a heart-lung machineVon Willebrand Disease (VWD)MedDRA version: 20.0Level: PTClassification code 10069495Term: Acquired Von Willebrand's diseaseSystem Organ Class: 10005329 - Blood and lymphatic system disordersEUCTR2017-003036-37-ATTirol Kliniken GmbH68
Active, not recruiting
Phase 1
A double-blind, placebo-controlled pilot trial of BP1.4979 for the treatment of binge eating disorderBinge eating disorder (BED)MedDRA version: 24.0Level: PTClassification code 10004716Term: Binge eatingSystem Organ Class: 10037175 - Psychiatric disordersEUCTR2021-000472-11-FRBIOPROJET PHARMA66
Active, not recruiting
Phase 1
A double-blind, placebo-controlled pilot trial of BP1.4979 for the treatment of binge eating disorder.Binge eating disorderMedDRA version: 21.1Level: PTClassification code: 10004716Term: Binge eating Class: 100000004873CTIS2023-506511-17-00Bioprojet Pharma86